AMPH — Amphastar Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for Amphastar Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	322	350	438	499	644
Cost of Revenue
Gross Profit	132	143	200	249	354
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	322	339	354	397	450
Operating Profit	-0.039	11	83.5	102	194
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	60.2	4.64	84.1	116	171
Provision for Income Taxes
Net Income After Taxes	46.5	1.1	63.5	92.6	140
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	48.9	1.4	62.1	91.4	138
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	48.9	1.4	62.1	91.4	138
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.054	-0.141	1.04	1.83	2.68